In the current study, we found that the combination therapy of EGFR–TKI, denosumab, and an anti‐VEGF agent significantly improved OS compared to EGFR–TKI monotherapy in patients with EGFR‐mutated NSCLC. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.